Issue 109

The Psychedelics as Medicine Report: Fourth Edition

On Tuesday, 29 November, PSYCH released the fourth edition of The Psychedelics as Medicine Report.

The report, expanded to include data on adult-use frameworks, contains market valuations and contributions from business leaders, researchers and regulators, empowering investors to make informed decisions.

It revealed the industry is currently worth US$650 million, and is expected to exceed US$3 billion by 2026. The next three years will be pivotal in the adoption of psychedelic healthcare, with MDMA and psilocybin-assisted therapies expected to be regulated on both sides of the Atlantic.

To navigate the rapidly changing landscape, The Psychedelics as Medicine Report provides a holistic overview of the interventions poised for market approval, and a balanced perspective of the related socioeconomic opportunities.

PSYCHEDELIC HEALTHCARE AND THE MENTAL HEALTH CRISIS

Current treatments for mental health conditions are often ineffective, with psychedelic medicines representing significant innovation.

RISE IN LONG-TERM SICKNESS POSES A THREAT TO UK ECONOMY

The Psychedelics as Medicine Report revealed psychedelic healthcare could save European economies US$130 billion in lost productivity.

BUSINESS AND INVESTMENT

Psychedelic healthcare industry to reach US$3b by 2026.

Emyria raises A$3m in private placement.

Awakn expands operations in Scandinavia.

Braxia reports Q3 2022 financial results.

Psychedelic medicines and treatment-resistant depression.

Sintalica approved to cultivate psilocybin-producing fungi in Italy.

Investment opportunities in psychedelic healthcare.

The route-to-market for psychedelic medicines.

The rise of at-home ketamine treatments.

Ketamine and esketamine safety concerns.

KGK Science and Nova Mentis to study psilocybin for Fragile X Syndrome.

Psilocybin services expand tourism in Jamaica.

Following the success of the SOLD OUT PSYCH Symposium in 2022, the industry-leading conference returns to the iconic British Museum on Thursday, 6 July 2023.

Super Early Bird tickets now on sale for £249 + VAT.

TICKET REGISTRATION

SCIENCE AND RESEARCH

NIMH outlines priorities for psychedelic research.

Race and ethnicity considerations in psychedelic research.

The impact of ketamine on synaptogenesis.

Beckley Foundation studies LSD for Alzheimer’s disease.

Psilocybin induced changes in music-evoked emotion.

Electroshock therapy compared with ketamine-assisted therapy.

Literature review on altered states of consciousness.

For industry intelligence, The Psychedelics as Medicine Report features contributions from and interviews with prominent business leaders, regulators, researchers and politicians.

Complimentary download: https://psych.global/report/

TICKET REGISTRATION

REGULATION AND LEGISLATION

New York’s regulation of psychedelic healthcare.

TheraPsil petitions for psilocybin accessibility in Canada.

Move to decriminalise LSD in Berkeley.

Colorado governor appoints psychedelic healthcare advisory panel.

ARTICLES OF INTEREST

UK loses 17 million working days to stress, depression and anxiety.

Music programming for psilocybin-assisted therapy.